Skip to content

Epidemiological Study to Assess the Prevalence of Lung Cancer

Epidemiological Study to Assess the Prevalence of Lung Cancer in Patients With Smocking-associated Atherosclerotic Cardiovascular Diseases

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03976804
Acronym
PREVALUNG
Enrollment
500
Registered
2019-06-06
Start date
2019-11-04
Completion date
2022-12-02
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Cardiovascular Event, Lung Cancer, Tobacco

Keywords

Cancer, Tobacco

Brief summary

Lung cancer is the main cause of mortality by cancer in France. The lung cancer stage at time of diagnosis is a major determinant of survival. To date, 75% of lung cancer are diagnosed at an advanced stage with worse survival). Lung cancer screening is based on low dose CT scan which allows to decrease lung cancer related mortality of 20% in patients aged 55-74 years-old with a history of tobacco consumption ≥ 30 PY active of who quite \< 15 years. These criteria for eligibility for lung cancer screening lead to 1 to 2% of lung cancer diagnosis at the first CT scan. In our experience regarding 1 year of lung cancer surgical resection, only 45% of the patients presented criteria for lung cancer screening. Moreover, the duration of tobacco consumption would provide a better stratification of lung cancer risk compared to only PY. Therefore, other criteria for lung cancer screening eligibility could be proposed. Currently, 9 out of 10 lung cancer is linked with tobacco consumption which is also a major risk factor for atherosclerosis-associated cardiovascular events. Around 40% of patients with a lung cancer have a history of atherosclerosis-associated cardiovascular event, mainly coronary artery diseases and peripheral artery diseases. Main Objective: The objective is to compare the observed rate of lung cancer prevalence in our study to the rate of around 2 % observed in lung cancer screening trials in south Europe (France and Italy). The investigators hypothesize that the population of patients with a history of atherosclerotic cardiovascular event associated with tobacco consumption present a higher prevalence of lung cancer compared with the population of patients eligible for lung cancer screening program which is defined by age and history of tobacco consumption.

Interventions

Lung cancer screening will be based on the analysis of a low dose CT scan

OTHERblood sample collection

establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota

OTHERfaecal sample collection

establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota

Sponsors

Centre Chirurgical Marie Lannelongue
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 45 - 75 years old * Patient who has signed an informed written consent * Daily smoking for at least 10 years * History of cardiovascular disease:

Exclusion criteria

* History of active cancer \< 5 years (except in situ cervical carcinoma and basal cell carcinoma of the skin) * Lung cancer symptoms (involuntary weight loss \> 6.8 kg in 1 year, hemoptysis) * Treatment or bleeding risk syndrome contraindicating an invasive diagnostic procedure within 3 months. * Active pulmonary parenchymal infection * Severe cardiac or respiratory insufficiency (resting dyspnea)

Design outcomes

Primary

MeasureTime frameDescription
prevalence of lung cancer19 monthsestimation of the prevalence of lung cancer among patients managed for atherosclerosis-related cardiovascular events associated with tobacco consumption.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026